The rise in obesity rates globally, especially in low- and middle-income countries, has led to a growing market for weight loss treatments. However, access to these treatments is limited in poorer nations, creating a potential increase in healthcare inequality. Companies developing anti-obesity drugs must consider equitable access plans to ensure all individuals have the opportunity to benefit from these advancements. The pharmaceutical industry needs to balance its focus on obesity medications with addressing other pressing medical needs, such as antibiotic development. While profits are essential, companies have a responsibility to prioritize global health and make treatments affordable for all.
Source link
Pharma companies must ensure equitable access to obesity drugs
